Mal-Deferoxamine

Mal-Deferoxamine is a maleamide (Mal) -containing Deferoxamine (HY-B1625) . Mal selectively covalently binds to sulfur groups to produce a linking reaction. Mal-Deferoxamine can be combined with radionuclides to synthesize radionuclide drug conjugates (RDCs) . RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.[1].

Product Specifications

CAS Number

[1638156-31-6]

UNSPSC

12352005

Target

Akt; Apoptosis; Autophagy; HIF/HIF Prolyl-Hydroxylase; Radionuclide-Drug Conjugates (RDCs) ; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Antibody-drug Conjugate/ADC Related; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/mal-deferoxamine.html

Purity

95.0

Solubility

DMSO : 83.33 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1C=CC(N1CCC(NCCCCCN(C(CCC(NCCCCCN(C(CCC(NCCCCCN(C(C)=O)O)=O)=O)O)=O)=O)O)=O)=O

Molecular Formula

C32H53N7O11

Molecular Weight

711.80

References & Citations

[1] Summer D, et al. Cyclic versus Noncyclic Chelating Scaffold for 89Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression. Mol Pharm. 2018;15 (1) :175-185.